CCNJL (cyclin J like) is a cyclin-dependent protein kinase regulator localized to the cytoplasm, nucleus, and microtubule organizing centers, with roles in G1/S transition of the mitotic cell cycle [GO Annotations]. The gene functions as a cyclin-dependent protein serine/threonine kinase regulator through protein binding interactions [GO Annotations]. CCNJL has emerged as a significant prognostic biomarker in hepatocellular carcinoma (HCC). It was identified as one of 18 genes in a hypoxia-glycolysis-lactate-related prognostic signature that independently predicts HCC prognosis and correlates with immune infiltration and somatic mutations 1. Additionally, CCNJL was incorporated into a disulfidptosis-related gene prognostic signature (DRGPS) as one of five key genes, where it associated with tumor microenvironment modulation, tumor mutation burden, and chemosensitivity prediction in HCC patients 2. Beyond HCC, CCNJL demonstrated prognostic value in colorectal cancer (CRC), appearing in a nine-gene prognostic signature where it was significantly downregulated as a target of hsa-miR-340, correlating with improved patient prognosis 3. The gene's involvement in immune-related processes suggests potential therapeutic relevance. However, specific mechanistic details regarding CCNJL's direct molecular functions remain largely unexplored in current literature.